NEW DELHI: Sun Pharma — India’s largest drugmaker — has reached a milestone as global sales of its innovative drugs crossed $1 billion in FY24, marking substantial growth for the company since it established its presence in the fast-growing US speciality market over a decade ago. Spurred by the huge potential, the company plans to … Read more
“I do not think the market is bracing for any kind of negative surprise at this point of time. And we do think that given the earnings that we have seen so far and the fact that we have underperformed US markets, there is a scope for some sort of an outperformance once the event … Read more
Shares of Sun Pharmaceutical Industries fell 5% in Thursday’s trade on BSE to the day’s low of Rs 1,467 even after the company posted a 34% year-on-year (YoY) jump in its Q4 profit to Rs 2,654.6 crore while the revenue rose 10.1% YoY to Rs. 11813 crore in Q4FY24. The board of the company also … Read more
Benchmark indices closed higher on Wednesday amid buying in blue chips even on the back of mixed cues from global markets. The 30-share Sensex climbed 267 points to settle at 74,221.06 and Nifty rose by 68 points to finish at 22,597. Stocks that were in focus include names like Indian Bank, which fell 1.33%, Sun … Read more
Various widely tracked companies like ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi’s lab will be releasing their March quarter report cards this week. Here’s a list: May 20ONGC, Indian Railway Finance Corporation (IRFC), Bharat Electronics (BEL), Oil India, SAIL, Deepak Nitrite, Whirlpool of India, … Read more
Brokerage firm HSBC maintained a buy rating on Sun Pharma, Citigroup recommended a buy rating on ICICI Bank, JPMorgan has an overweight rating on Bajaj Finance and CLSA recommended a buy rating on Avenue Supermarts. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: HSBC on Sun Pharma: … Read more
Technical analysts continue to maintain a cautious outlook on Nifty for the truncated trading week ahead. According to analysts, profit-taking may resume until the index decisively reclaims 22,200. Some of the stocks recommended by analysts for short-term trades include Apollo Hospitals, Eicher Motors, Hero Motocorp, Maruti, Bajaj Auto, Sun Pharma, Tata Motors, ABB, Cummins India, … Read more
Technical charts indicate the market appears poised to sustain its upward momentum going ahead. Technical analysts predict Nifty is likely to advance towards 22,600, followed by 23,000, with robust support at 21,920. They suggest stocks such as Oracle Finance, HDFC Life, Marico, Pidilite, ICICI Bank, Maruti, Cipla, Sun Pharma, Larsen & Toubro, PNB, HAL, and … Read more
Indian market is likely to consolidate and head higher on Thursday tracking the positive trend seen in other Asian markets. The Nifty future closed positive with gains of 0.75% at 22602 levels on Wednesday. India VIX fell 0.59%, ending the day below 14.30. This was the sixth trading session in a row where the fear … Read more
Brokerage firm Macquarie maintained a neutral rating on Paytm, BofA Securities recommended a neutral rating on Sun Pharma, and Elara Capital maintained an accumulate rating on KEC International and M&M Financial Services. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Macquarie on Paytm: Neutral| Target Rs 650 … Read more